A Curative Combination Cancer Therapy Achieves High Fractional Cell Killing Through Low Cross-resistance and Drug Additivity

Overview

Journal Elife

Specialty Biology

Date 2019 Nov 20

PMID 31742555

Citations 67

Authors

Adam C Palmer

Christopher Chidley

Peter K Sorger

Affiliations

Soon will be listed here.

Abstract

Curative cancer therapies are uncommon and nearly always involve multi-drug combinations developed by experimentation in humans; unfortunately, the mechanistic basis for the success of such combinations has rarely been investigated in detail, obscuring lessons learned. Here, we use isobologram analysis to score pharmacological interaction, and clone tracing and CRISPR screening to measure cross-resistance among the five drugs comprising R-CHOP, a combination therapy that frequently cures Diffuse Large B-Cell Lymphomas. We find that drugs in R-CHOP exhibit very low cross-resistance but not synergistic interaction: together they achieve a greater fractional kill according to the null hypothesis for both the Loewe dose-additivity model and the Bliss effect-independence model. These data provide direct evidence for the 50 year old hypothesis that a curative cancer therapy can be constructed on the basis of independently effective drugs having non-overlapping mechanisms of resistance, without synergistic interaction, which has immediate significance for the design of new drug combinations.

Citing Articles

A Bayesian active learning platform for scalable combination drug screens.

Tosh C, Tec M, White J, Quinn J, Ibanez Sanchez G, Calder P Nat Commun. 2025; 16(1):156.

PMID: 39746987 PMC: 11696745. DOI: 10.1038/s41467-024-55287-7.

Multi-Component, Time-Course screening to develop combination cancer therapies based on synergistic toxicity.

Ceribelli M, Tosto F, Zhang X, Melani C, Roschewski M, Beck E Proc Natl Acad Sci U S A. 2024; 121(49):e2413372121.

PMID: 39585996 PMC: 11626182. DOI: 10.1073/pnas.2413372121.

Three-dimensional analysis of mitochondria in a patient-derived xenograft model of triple negative breast cancer reveals mitochondrial network remodeling following chemotherapy treatments.

Berner M, Beasley H, Vue Z, Lane A, Vang L, Baek M bioRxiv. 2024; .

PMID: 39314272 PMC: 11419075. DOI: 10.1101/2024.09.09.611245.

Construction and Evaluation of BAL-PTX Co-Loaded Lipid Nanosystem for Promoting the Anti-Lung Cancer Efficacy of Paclitaxel and Reducing the Toxicity of Chemotherapeutic Drugs.

Chen T, Wei Y, Yin S, Li W, Wang Y, Pi C Int J Nanomedicine. 2024; 19:7775-7797.

PMID: 39099795 PMC: 11297572. DOI: 10.2147/IJN.S474158.

ASCT2 is a major contributor to serine uptake in cancer cells.

Conger K, Chidley C, Ozgurses M, Zhao H, Kim Y, Semina S Cell Rep. 2024; 43(8):114552.

PMID: 39068660 PMC: 11406281. DOI: 10.1016/j.celrep.2024.114552.

References

Kampmann M, Bassik M, Weissman J . Integrated platform for genome-wide screening and construction of high-density genetic interaction maps in mammalian cells. Proc Natl Acad Sci U S A. 2013; 110(25):E2317-26. PMC: 3690882. DOI: 10.1073/pnas.1307002110. View

Pritchard J, Bruno P, Gilbert L, Capron K, Lauffenburger D, Hemann M . Defining principles of combination drug mechanisms of action. Proc Natl Acad Sci U S A. 2012; 110(2):E170-9. PMC: 3545813. DOI: 10.1073/pnas.1210419110. View

Frei 3rd E, Elias A, Wheeler C, Richardson P, Hryniuk W . The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity. Clin Cancer Res. 1998; 4(9):2027-37. View

Sanger W, EISEN J . Clastogenic effects of methylnitrosourea and ethylnitrosourea on chromosomes from human fibroblast cell lines. Mutat Res. 1976; 34(3):415-26. DOI: 10.1016/0027-5107(76)90219-0. View

Cokol M, Kuru N, Bicak E, Larkins-Ford J, Aldridge B . Efficient measurement and factorization of high-order drug interactions in . Sci Adv. 2017; 3(10):e1701881. PMC: 5636204. DOI: 10.1126/sciadv.1701881. View

Sebastian E, Alcoceba M, Martin-Garcia D, Blanco O, Sanchez-Barba M, Balanzategui A . High-resolution copy number analysis of paired normal-tumor samples from diffuse large B cell lymphoma. Ann Hematol. 2015; 95(2):253-62. DOI: 10.1007/s00277-015-2552-3. View

Goel S, Wang Q, Watt A, Tolaney S, Dillon D, Li W . Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. Cancer Cell. 2016; 29(3):255-269. PMC: 4794996. DOI: 10.1016/j.ccell.2016.02.006. View

Hutchison D . Conference on obstacles to the control of acute leukemia. Studies on cross-resistance and collateral sensitivity (1962-1964). Cancer Res. 1965; 25(9):1581-95. View

Frei 3rd E . Combination cancer therapy: Presidential address. Cancer Res. 1972; 32(12):2593-607. View

10.

Tran L, Baars J, Aarden L, Beijnen J, Huitema A . Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies. Hum Antibodies. 2010; 19(1):7-13. DOI: 10.3233/HAB-2010-0215. View

11.

Davidoff A, Mendelow B . Cell-cycle disruptions and apoptosis induced by the cyclophosphamide derivative mafosfamide. Exp Hematol. 1993; 21(7):922-7. View

12.

Chait R, Craney A, Kishony R . Antibiotic interactions that select against resistance. Nature. 2007; 446(7136):668-71. DOI: 10.1038/nature05685. View

13.

Lakhtakia R, Burney I . A Historical Tale of Two Lymphomas: Part II: Non-Hodgkin lymphoma. Sultan Qaboos Univ Med J. 2015; 15(3):e317-21. PMC: 4554264. DOI: 10.18295/squmj.2015.15.03.003. View

14.

Alizadeh A, Eisen M, Davis R, Ma C, Lossos I, Rosenwald A . Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403(6769):503-11. DOI: 10.1038/35000501. View

15.

Shalem O, Sanjana N, Hartenian E, Shi X, Scott D, Mikkelson T . Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 2013; 343(6166):84-87. PMC: 4089965. DOI: 10.1126/science.1247005. View

16.

Roberts A, Ward C, Nomura D . Activity-based protein profiling for mapping and pharmacologically interrogating proteome-wide ligandable hotspots. Curr Opin Biotechnol. 2016; 43:25-33. PMC: 5305418. DOI: 10.1016/j.copbio.2016.08.003. View

17.

Hafner M, Niepel M, Chung M, Sorger P . Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs. Nat Methods. 2016; 13(6):521-7. PMC: 4887336. DOI: 10.1038/nmeth.3853. View

18.

Eden E, Navon R, Steinfeld I, Lipson D, Yakhini Z . GOrilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists. BMC Bioinformatics. 2009; 10:48. PMC: 2644678. DOI: 10.1186/1471-2105-10-48. View

19.

Ribera J, Oriol A, Morgades M, Gonzalez-Barca E, Miralles P, Lopez-Guillermo A . Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. Br J Haematol. 2007; 140(4):411-9. DOI: 10.1111/j.1365-2141.2007.06943.x. View

20.

Palmer A, Sorger P . Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy. Cell. 2017; 171(7):1678-1691.e13. PMC: 5741091. DOI: 10.1016/j.cell.2017.11.009. View